Drug · CHEMBL24
ATENOLOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ATENOLOL. Drugs and targets, record CHEMBL24. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL24
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Antipressan, Atenamin, Atenix-100, Atenix-25, Atenix-50, Atenolol component of polycap, Atenolol component of tenoretic, Ibinolo, Kentol, Tenormin, Tenormin 25, Tenormin l.s., Totamol, Unibloc, Vasaten
- ChEMBL
- Other names
- Atenololum, Betacard, C07AB03, Corotenol, Duraatenolol, ICI 66,082, ICI 66082, ICI-66082, Juvental, Myocord, NSC-757832, Novaten, Prenormine, Urosin
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 34 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | Beta-1 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/153 |
Source ChEMBL
Diseases34
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 34Source Open Targets
See all 34 diseasesTrials95
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 49 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00246519 | Pharmacogenomic Evaluation of Antihypertensive Responses | Phase 4 | 1,701 | 2013-07-10 | atenolol | Its name | ClinicalTrials.gov |
| NCT00535925 | Nephropathy In Type 2 Diabetes and Cardio-renal Events | Phase 4 | 850 | 2020-05-11 | atenolol | Its name | ClinicalTrials.gov |
| NCT00429364 | Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome | Phase 3 | 608 | 2015-04-01 | atenolol | Its name | ClinicalTrials.gov |
| NCT01404078 | Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium | 518 | 2014-12-01 | polycap | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov | |
| NCT02342275 | Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma | Phase 3 | 377 | 2022-06-16 | atenolol | Its name | ClinicalTrials.gov |
| NCT00108082 | The CLEVER Study - Coreg And Left Ventricular Mass Regression | Phase 3 | 287 | 2009-11-09 | atenolol | Its name | ClinicalTrials.gov |
| NCT01079962 | An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION]) | Phase 4 | 209 | 2012-10-02 | atenolol | Its name | ClinicalTrials.gov |
| NCT00582114 | Hypertension in Hemodialysis Patients (Aim 3) | Phase 3 | 200 | 2016-01-18 | atenolol | Its name | ClinicalTrials.gov |
| NCT01251146 | A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension | Phase 4 | 177 | 2012-11-30 | atenolol | Its name | ClinicalTrials.gov |
| NCT00837902 | Genetic Determinants of Response to Beta Blockade | 154 | 2018-11-30 | atenolol | Its name | ClinicalTrials.gov |
1 to 10 of 95
See all 95 trialsComparisons in its trials37
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Propranolol or Carvedilol vs Atenolol, Bisoprolol or Sotalol: deaths from any cause | 0 of 222,015 | 0 of 222,015 | 444,030 | NCT05794997 | Trial comparisons |
| Atenolol +HCTZ Arm vs HCTZ + Atenolol: serious adverse events | 1 of 386 | 3 of 382 | 768 | NCT00246519 | Trial comparisons |
| Atenolol vs Losartan: Number of Death. | 0 of 303 | 1 of 305 | 608 | NCT00429364 | Trial comparisons |
| Atenolol vs Losartan: Number of Participants With Aortic-root Surgery. | 10 of 303 | 18 of 305 | 608 | NCT00429364 | Trial comparisons |
| Atenolol vs Losartan: Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death. | 10 of 303 | 19 of 305 | 608 | NCT00429364 | Trial comparisons |
| Atenolol vs Losartan: Number of Participants With Aortic Dissection. | 0 of 303 | 2 of 305 | 608 | NCT00429364 | Trial comparisons |
| Atenolol vs Losartan: serious adverse events | 27 of 303 | 33 of 305 | 608 | NCT00429364 | Trial comparisons |
| Conventional Therapy vs Intensified Therapy: Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs) | 146 of 188 | 116 of 207 | 395 | NCT00535925 | Trial comparisons |
| Conventional Therapy vs Intensified Therapy: deaths from any cause | 103 of 188 | 86 of 207 | 395 | NCT00535925 | Trial comparisons |
| Conventional Therapy vs Intensified Therapy: serious adverse events | 88 of 188 | 69 of 207 | 395 | NCT00535925 | Trial comparisons |
1 to 10 of 37
See all 37 comparisons in its trialsPapers from its trials195
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL24
GET https://conductscience.org/api/drugs/v1/CHEMBL24/diseases?page=2